Second‐line treatments and outcomes for immune thrombocytopenia: A retrospective study with electronic health records-Reference-Cited by-同舟云学术

Second‐line treatments and outcomes for immune thrombocytopenia: A retrospective study with electronic health records

Published:2020-09-11 Issue:7 Volume:4 Page:1131-1140
ISSN:2475-0379
Container-title:Research and Practice in Thrombosis and Haemostasis
language:en
Short-container-title:Res Pract Thromb Haemost

Author:

Lal Lincy S.¹,Said Qayyim²,Andrade Katherine¹,Cuker Adam³

Affiliation:

1. Optum Health Economics and Outcomes Research Eden Prairie MN USA

2. Novartis Pharmaceuticals Corporation East Hanover NJ USA

3. Department of Medicine and Department of Pathology & Laboratory Medicine Perelman School of Medicine University of Pennsylvania Philadelphia PA USA

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/rth2.12423

Reference29 articles.

1. Primary immune thrombocytopenia in US clinical practice: incidence and healthcare burden in first 12 months following diagnosis

2. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia

3. American Society of Hematology 2019 guidelines for immune thrombocytopenia

4. Immune thrombocytopenia: pathogenesis and treatment approaches;Raj AB;J Hematol Transfus,2017

5. Changes in health-related quality of life with long-term eltrombopag treatment in adults with persistent/chronic immune thrombocytopenia: Findings from the EXTEND study

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment patterns and outcomes among adults with immune thrombocytopenia receiving pharmaceutical second-line therapies: a retrospective cohort study using administrative claims data;Current Medical Research and Opinion;2024-03-25

2. Vücut Kitle İndeksi ve Kan Gruplarının İmmün Trombositopeni Tedavisine Etkisi;Harran Üniversitesi Tıp Fakültesi Dergisi;2023-08-31

3. Therapeutic Outcomes of High Dose-Dexamethasone versus Prednisolone + Azathioprine, Rituximab, Eltrombopag, and Romiplostim Strategies in Persistent, Chronic, Refractory, and Relapsed Immune Thrombocytopenia Patients;Pharmaceuticals;2023-08-29

4. Bisphosphonate use for glucocorticoid-induced osteoporosis in older patients with immune thrombocytopenia: a clinical perspective;Annals of Hematology;2023-05-12

5. Treatment patterns and outcomes of second-line rituximab and thrombopoietin receptor agonists in adult immune thrombocytopenia: A Canadian retrospective cohort study;Thrombosis Research;2022-12